POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.673 EUR | +1.97% |
|
+2.91% | +22.14% |
| 11/04 | Poxel: CDC falls below the 10% threshold | CF |
| 15/02 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 13.4M 14.32M 1.19B | Sales 2022 | 674K 721K 60.11M | Capitalization | 27.16M 29.04M 2.42B |
|---|---|---|---|---|---|
| Net income 2021 | -23M -24.59M -2.05B | Net income 2022 | -31M -33.15M -2.76B | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.21M 268M | Net Debt 2022 | 32.74M 35M 2.92B | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
| 1 day | +1.97% | ||
| 1 week | +2.91% | ||
| Current month | +29.92% | ||
| 1 month | +37.07% | ||
| 3 months | +41.24% | ||
| 6 months | +89.58% | ||
| Current year | +22.14% |
1 week
0.64
0.90
1 month
0.530.90
Current year
0.360.90
1 year
0.300.95
3 years
0.307.75
5 years
0.3013.80
10 years
0.3017.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 06/09/06 | |
Sebastien Bolze
FOU | Founder | - | 06/09/06 |
| Founder | - | 06/09/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 12/15/12 |
Pascale Boissel
BRD | Director/Board Member | 57 | 05/15/05 |
Thomas Kuhn
FOU | Founder | 50 | 06/09/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.673 | +1.97% | 495,428 |
| 25/24/25 | 0.66 | -12.47% | 692,760 |
| 24/24/24 | 0.754 | -2.08% | 799,122 |
| 23/24/23 | 0.77 | -2.65% | 975,745 |
| 22/24/22 | 0.791 | +20.95% | 917,394 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
16/05/2024
- Q1 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +22.14% | 27.84M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- POXEL Stock
